Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Features

Features
Type 2 diabetes as a risk factor for Alzheimer's disease - defective insulin-degrading enzyme as an etiological link?

02 Apr 04

DailyUpdates 2nd April: There is growing evidence that type-2 diabetes is a risk factor for Alzheimer disease. In their April American Journal of Pathology article Brigham and Women's Hospital researchers add further evidence to support defects in insulin-degrading enzyme activity as a potential cause of this phenomenon. This and similar data argues for the development of cross-indication treatments of type-2 diabetes and Alzheimer disease and GSK-3 inhibitors may fit the bill.
LeadDiscovery

GREES publish new recommendations on the clinical development of disease modifying osteoarthritis drugs (DMOADs)

01 Apr 04

DailyUpdates 1st April: Osteoarthritis is the most common form of arthritis and is estimated to affect over 73 million people in the seven major pharmaceutical markets. Disease modifying osteoarthritis drugs (DMOADs) currently represent the ‘holy grail’ in the treatment of osteoarthritis. The Group for the Respect of Ethics and Excellence in Science (GREES) have now published recommendations on the clinical development of DMOADs.
LeadDiscovery

Merck & Co develop new leads for the treatment of bipolar disorder through the development of a new HTS assay of inositol monophosphatase inhibitors

31 Mar 04

DailyUpdates 31st March: Bipolar disorder affects over 2 million people in the US alone. Lithium, which inhibits inositol monophosphatase, has long been a first line mood stabilizer used in the treatment of this condition. Merck & Co have now developed a new cell-based HTS assay to identify novel inositol monophosphatase inhibitors which will hopefully lead to improved treatments of bipolar disorder.
LeadDiscovery

Sulfonylureas vs thiazolidinediones for the prevention of diabetic nephropathy

30 Mar 04

DailyUpdates 30th March: According to WHO, there are some 130 million diagnosed diabetics in the world and the long term consequences of diabetes such as diabetic nephropathy are becoming increasingly frequent and unmet components of diabetes care. Intensive glycemic control prevents or retards microalbuminuria, an early sign of nephropathy in patients with type 2 diabetes and in a recent study Japanese researchers compare two different classes of oral antidiabetic drugs with respect to their e
LeadDiscovery

New data published on KW-7158, a novel treatment of overactive bladder

29 Mar 04

Overactive bladder, a condition associated with a variety of other pathologies affects over 17 million Americans and costs the US over $12 billion per year. Current treatments focus on the muscarinic receptor antagonists such as tolterodine and oxybutanin with further examples from this class expected on the market. Therapeutics from novel pharmacological classes are expected to offer further improvements and in an upcoming edition of the Journal of Pharmacology & Experimental Therapeutics Uni
LeadDiscovery

Naked Ambition

28 Mar 04

The presence of Arthur Dent's in pyjamas throughout the Hitch Hiker's Guide to the Galaxy, in a series of increasingly surreal encounters, acts as a constant reminder to the reader that no matter what
Daniel Judge

All in the name of research

25 Mar 04

Andrew Curl from the ABPI explains more about the industry's ability to innovate and provide world-beating medicines.
Claire Richland

Finding the Next Asian Pharma Sensation

19 Mar 04

Japan has always been considered the technology pioneer of Asia, however, in recent years a number of other countries in this region have placed significant emphasis on industrial and technological performance in order to improve their own world position. One industry that is developing rapidly in the region is the pharmaceutical industry.
Dr Faiz Kermani and Dr Rebecca Gittins

Pharma NewsBytes: 6th February

13 Feb 04

Pharma NewsBytes selects out what we consider as being some of the most interesting press releases to have appeared on our DailyUpdates tracking service over the past few weeks. Currently featured new items focus on a number of novel approaches to the treatment of cancer including the development of caspase inhibitors; gene therapy approaches to the expression of TNF-alpha; an advanced monoclonal antibody; and a strategy to block XIAP. In addition new therapeutics for the treatment of rheumatoid
LeadDiscovery

The effects of insulin on airway function: repercussions for intra-tracheal insulin delivery and for asthma therapeutics

13 Feb 04

According to WHO, there are some 130 million diagnosed diabetics in the world. The market for diabetes therapeutics is rising. Oral antidiabetic drugs, the leading class of drugs used to treat the disease, accounted for almost 63% of sales during this period, while sales of insulin stand at around 30%. Further increases are inevitable and the market for diabetes medications could exceed $20 billion by 2006. The largest unmet need in the diabetes market is improved delivery of insulin. Currently,
LeadDiscovery

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.